About Cerus:
Cerus aims to be the global leader and trusted partner of blood centers and hospitals whose technology, services, and commitment are the lifeblood of safe and accessible blood for patients around the world.
Overarching Objective: Develop an understanding of how to assess product opportunities and develop go to market global strategies for novel medical device products in the field of transfusion medicine. In parallel, work with Investor Relations on a variety of topics to develop an understanding of NASDAQ public company IR efforts.
Goals for 6 week summer program:
- Use various AI Deep Research Tools (Gemini, Claude, Perplexity etc.) for below projects and catalogue utility for future use by Cerus team
- Develop value proposition rationale for INTERCEPT RBC go-to-market strategy
- Business development efforts – identify opportunities for PRPCR outlet to monetize -- use in cell culture media preparations or other uses
- Lyophilized plasma business plan
- AI Agents for Product Management
Develop Investor Relations Messaging
Assessing INTERCEPT RBC U.S. red blood cell transfusion market opportunity
- How many deferred donors (based on May 2023 U.S. FDA recommendations for evaluating donor eligibility) could be recaptured with INTERCEPT RBC
- What percent of the RBC are irradiated?
- Economics or irradiated red cells
- What percent of RBC are washed?
- Economics of washed RBC
- CMV seronegative RBC – how large a segment is that?
- Economics of CMV seronegative RBC
- Babesia and Lyme Disease Testing – how large a segment is that?
- Economics of Babesia and Lyme Disease Testing
Expanding Wall Street Coverage
Identifying investment banks that have capabilities and the bandwidth to potentially add Cerus to their coverage
- What banks have MedTech/diagnostic/life science analysts with capacity to add more companies?
- Identify analyst with non-focused coverage (not focused on a single sub-sector – i.e. cardio or ophthalmology only. Someone that just covers Ortho won’t add CERS to his/her names)
Valuation Assessment
Develop regression model - plotting the valuation of CERS and its peers
EV/Sales vs. Sales growth
Can we add a third parameter? How to include “cash runway” on impact on valuation? Positive cash flow = infinite runway.
Organizational / record keeping
Help catalogue historical IR files (presentations, press releases, presentations) in Box
Hourly rate: $18/hr
Similar Jobs
.png)
What We Do
Cerus Corporation is dedicated solely to safeguarding the world’s blood supply and aims to become the preeminent global blood products company. Headquartered in Concord, California, the company develops and supplies vital technologies and pathogen-protected blood components to blood centers, hospitals, and ultimately patients who rely on safe blood. The INTERCEPT Blood System for platelets and plasma is available globally and remains the only pathogen reduction system with both CE mark and FDA approval for these two blood components. The INTERCEPT red blood cell system is under regulatory review in Europe, and in late-stage clinical development in the US. Also in the US, the INTERCEPT Blood System for Cryoprecipitation is approved for production of INTERCEPT Fibrinogen Complex, a therapeutic product for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. For more information about Cerus, visit www.cerus.com and follow us on LinkedIn.
